Lars Lund

AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021.

AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021.

AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021.

AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021.

AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021.